Dechra Pharmaceuticals PLC
Dechra Pharmaceuticals PLC (DPHAY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
dphay · pe ratio · data through Jun 30, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Dechra Pharmaceuticals PLC (DPHAY) measures how much investors pay for each dollar of the company's trailing earnings. DPHAY's current PE ratio of N/A is calculated by dividing its stock price of $98.00 by its TTM earnings per share of -$0.25.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-06-30
PE Ratio History
2004 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%221.4x
MedianQ3 · 75%413.4x
Max
At N/A, DPHAY's current P/E is lower than in 0% of its annual fiscal year readings over the past 19 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - General · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Dechra Pharmaceuticals PLCYou DPHAY | $5.6B | N/A | — | -$0.25 |
 Abcam plc ABCZF | $5.1B | N/A | — | $0.00 |
 Mediclinic International plc ANHGY | $4.0B | N/A | — | — |
 Ascentage Pharma Group International ASPHF | $1.7B | N/A | — | -$3.40 |
 McKesson Europe AG CAKFY | $5.4B | N/A | — | -$0.05 |
 Galenica AG GALNF | $5.7B | 25.35x | -3.0% | $3.63 |
 Hangzhou Tigermed Consulting Co., Ltd. HNGZY | $6.2B | 26.89x | +3.0% | $1.04 |
Industry Average 2 peers with valid PE | — | 26.12x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-06-30Latest FY2023 | — | $-0.25 | — | |
2022-06-30 FY2022 | 106.24x | $0.54 | +8.5% | |
2021-06-30 FY2021 | 97.90x | $0.51 | -42.6% | |
2020-06-30 FY2020 | 170.50x | $0.33 | -11.1% | |
2019-06-30 FY2019 | 191.81x | $0.30 | +38.7% | |
2018-06-30 FY2018 | 138.27x | $0.37 | -25.6% | |
2017-06-30 FY2017 | 185.89x | $0.28 | -48.5% | |
2016-06-30 FY2016 | 361.07x | $0.14 | +84.7% | |
2015-06-30 FY2015 | 195.45x | $0.22 | +232.5% | |
2014-06-30 FY2014 | 58.79x | $0.68 | -72.9% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Dechra Pharmaceuticals PLC (DPHAY) measures how much investors pay for each dollar of the company's trailing earnings. DPHAY's current PE ratio of N/A is calculated by dividing its stock price of $98.00 by its TTM earnings per share of -$0.25.
Frequently asked questions
DPHAY pe ratio · 6 questionsDPHAY's current PE ratio is N/A as of 2026-06-08, based on a stock price of $98.00 and TTM EPS of -$0.25. Data sourced from Financial Modeling Prep via DPHAY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Dechra Pharmaceuticals PLC SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08